|
|
Time |
Source |
|
Announcement
|
|
| 18 Feb 2021 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis |
| 17 Feb 2021 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial |
| 11 Feb 2021 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 |
| 05 Jan 2021 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor Conferences in January |
| 24 Nov 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor Conferences in December |
| 17 Nov 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board |
| 10 Nov 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor and Scientific Conferences in November |
| 02 Nov 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed |
| 20 Oct 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy |
| 29 Sep 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Scientific Conferences in October |
| 28 Sep 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19 |
| 11 Sep 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020 |
| 08 Sep 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Scientific and Investor Conferences in September |
| 20 Aug 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| 02 Aug 2020 |
8:00 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis |
| 30 Jul 2020 |
9:15 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update |
| 29 Jul 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor Conferences in August |
| 27 Jul 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19 |
| 22 Jun 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Join Russell 3000(R) Index |
| 15 Jun 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 |
| 09 Jun 2020 |
12:00 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 |
| 29 May 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor and Industry Conferences in June |
| 19 May 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020 |
| 13 May 2020 |
9:01 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients |
| 21 Apr 2020 |
9:01 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients |
| 17 Apr 2020 |
10:00 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Changes to Executive Team |
| 11 Feb 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Scientific and Investor Conferences in February |
| 08 Jan 2020 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd. |
| 10 Oct 2019 |
9:01 pm |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis |
| 30 Sep 2019 |
11:30 am |
EQS
|
|
|
Immunic, Inc. |
Immunic, Inc. to Participate in Investor and Scientific Conferences in October |